Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New shareholder

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 18, 2024 8:10pm

92 Views

Post# 35997100

RE:RE:RE:RE:RE:RE:RE:New shareholder

Sorry new shareholder spessestsemper, you have it all wrong, since ONCY is not a startup and none of us are interested in either biobucks or or equity in exchange for a percentage of the company.

We have are seeking an all cash acquisition of ONCY and no airy fairy business development deal, the kind that you've tried to describe.

If ONCY managementis prudent such an all cash acquisitionof ONCY will happen before June 25, 2024.. If they aren't, then everyone stands to loose a significant portion of an of their capital gains through the increase inclusion capital gains tax announced by the Canadian Federal Government, earlier this week.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for June 17, 2024